Ghent University Academic Bibliography

Advanced

Magnetic resonance imaging to assess the resectability after chemoradiation of primary irresectable cervical Cancer

Louke Delrue UGent, Katrien Vandecasteele UGent, Bieke Lambert UGent, Amin Makar UGent, Kathleen Lambein UGent, Geert Villeirs UGent, PHILIPPE TUMMERS UGent, Wilfried De Neve UGent, Hannelore Denys UGent and Gert De Meerleer UGent (2009) RSNA, Abstracts.
abstract
Purpose: To assess the value of T2-weighted magnetic resonance imaging (MRI) in predicting resectability of primary irresectable cervical carcinoma (ICC) after neo-adjuvant chemoradiation therapy (CRT). Materials and Methods: Eleven patients with primary ICC (FIGO IIB-IVA) received pre-operative CRT consisting of intensity-modulated arc therapy (IMAT) ± cisplatin 40 mg/m² weekly. Four weeks after CRT, MRI was performed to evaluate resectability, defined as ≤ non-bulky FIGO IB-IIA disease. Surgery consisted of extra-fascial radical hysterectomy (EFRH) and was performed 6-8 weeks after CRT. Pathological examination included histology (H&E) and immuno-histochemistry (cytokeratin). The cervix was completely sectioned in all case! s. Results: Pre-CRT, MRI revealed FIGO IIB-IVA carcinoma in all cases. After CRT and EFRH, pathological examination showed ypT1B1, ypT1A and ypT0 in 3, 3 and 5 patients. Of the 11 positive pre-CRT MRI, 9 became negative after CRT (endpoint: ≤ non-bulky FIGO IB-IIA), which was confirmed by pathology in all 9 (true negatives concerning ≤ non-bulky FIGO IB-IIA). False positive results (n=2) were attributable to post-CRT fibrosis causing hydro-ureter (FIGO IIIB) and to a too long delay (42 days) between MRI (showing FIGO IIB) and EFRH (showing FIGO ypT1B1). Conclusion: MRI is an excellent modality to predict resectability of primary irresectable cervical cancer.
Please use this url to cite or link to this publication:
author
organization
year
type
conference
publication status
published
subject
keyword
cervical cancer, MRI, chemoradiotherapy response, prediction of resectability
in
RSNA, Abstracts
publisher
Radiological Society of North America (RSNA)
conference name
RSNA 2009 : Quality counts
conference location
Chicago, IL, USA
conference start
2009-11-29
conference end
2009-12-04
language
English
UGent publication?
yes
classification
C3
id
879258
handle
http://hdl.handle.net/1854/LU-879258
date created
2010-02-24 15:18:32
date last changed
2015-02-02 13:53:20
@inproceedings{879258,
  abstract     = {Purpose: To assess the value of T2-weighted magnetic resonance imaging (MRI) in predicting resectability of primary irresectable cervical carcinoma (ICC) after neo-adjuvant chemoradiation therapy (CRT).
Materials and Methods: Eleven patients with primary ICC (FIGO IIB-IVA) received pre-operative CRT consisting of intensity-modulated arc therapy (IMAT) {\textpm} cisplatin 40 mg/m{\texttwosuperior} weekly. Four weeks after CRT, MRI was performed to evaluate resectability, defined as \ensuremath{\leq} non-bulky FIGO IB-IIA disease. Surgery consisted of extra-fascial radical hysterectomy (EFRH) and was performed 6-8 weeks after CRT. Pathological examination included histology (H\&E) and immuno-histochemistry (cytokeratin). The cervix was completely sectioned in all case! s.
Results: Pre-CRT, MRI revealed FIGO IIB-IVA carcinoma in all cases. After CRT and EFRH, pathological examination showed ypT1B1, ypT1A and ypT0 in 3, 3 and 5 patients. Of the 11 positive pre-CRT MRI, 9 became negative after CRT (endpoint: \ensuremath{\leq} non-bulky FIGO IB-IIA), which was confirmed by pathology in all 9 (true negatives concerning \ensuremath{\leq} non-bulky FIGO IB-IIA). False positive results (n=2) were attributable to post-CRT fibrosis causing hydro-ureter (FIGO IIIB) and to a too long delay (42 days) between MRI (showing FIGO IIB) and EFRH (showing FIGO ypT1B1).
Conclusion: MRI is an excellent modality to predict resectability of primary irresectable cervical cancer.},
  author       = {Delrue, Louke and Vandecasteele, Katrien and Lambert, Bieke and Makar, Amin and Lambein, Kathleen and Villeirs, Geert and TUMMERS, PHILIPPE and De Neve, Wilfried and Denys, Hannelore and De Meerleer, Gert},
  booktitle    = {RSNA, Abstracts},
  keyword      = {cervical cancer,MRI,chemoradiotherapy response,prediction of resectability},
  language     = {eng},
  location     = {Chicago, IL, USA},
  publisher    = {Radiological Society of North America (RSNA)},
  title        = {Magnetic resonance imaging to assess the resectability after chemoradiation of primary irresectable cervical Cancer},
  year         = {2009},
}

Chicago
DELRUE, LOUKE, Katrien Vandecasteele, Bieke Lambert, Amin Makar, Kathleen Lambein, Geert Villeirs, Philippe Tummers, Wilfried De Neve, Hannelore Denys, and Gert De Meerleer. 2009. “Magnetic Resonance Imaging to Assess the Resectability After Chemoradiation of Primary Irresectable Cervical Cancer.” In RSNA, Abstracts. Radiological Society of North America (RSNA).
APA
DELRUE, LOUKE, Vandecasteele, K., Lambert, B., Makar, A., Lambein, K., Villeirs, G., Tummers, P., et al. (2009). Magnetic resonance imaging to assess the resectability after chemoradiation of primary irresectable cervical Cancer. RSNA, Abstracts. Presented at the RSNA 2009 : Quality counts, Radiological Society of North America (RSNA).
Vancouver
1.
DELRUE L, Vandecasteele K, Lambert B, Makar A, Lambein K, Villeirs G, et al. Magnetic resonance imaging to assess the resectability after chemoradiation of primary irresectable cervical Cancer. RSNA, Abstracts. Radiological Society of North America (RSNA); 2009.
MLA
DELRUE, LOUKE, Katrien Vandecasteele, Bieke Lambert, et al. “Magnetic Resonance Imaging to Assess the Resectability After Chemoradiation of Primary Irresectable Cervical Cancer.” RSNA, Abstracts. Radiological Society of North America (RSNA), 2009. Print.